Advocacy intelligence hub — real-time data for patient organizations
Alkermes, Inc. — PHASE3
University of Utah — NA
Eisai Inc. — PHASE2
Alkermes, Inc. — PHASE3
University Hospital, Toulouse — NA
Takeda — PHASE3
Jazz Pharmaceuticals — PHASE1
Takeda — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance3
Lumryz
(sodium oxybate)Orphan drugFlamel Ireland Limited dba Avadel Ireland
WAKIX
(Pitolisant)Orphan drugHarmony Biosciences Management, Inc.
12.1 Mechanism of Action The mechanism of action of pitolisant in excessive daytime sleepiness (EDS) or cataplexy in patients 6 years and older with n...
Xywav
(calcium, magnesium, potassium, and sodium oxybates)Orphan drugJazz Pharmaceuticals Ireland Limited
12.1 Mechanism of Action XYWAV is a CNS depressant. The exact mechanism of action of XYWAV in the treatment of narcolepsy and idiopathic hypersomnia i...
Sunosi
(Solriamfetol)Orphan drugAxsome Malta, Ltd.
Dopamine and Norepinephrine Reuptake Inhibitor [EPC]
12.1 Mechanism of Action The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with ...
Giuseppe Plazzi
IRCCS Istituto delle Scienze Neurologiche di Bologna
Grace Wang, MD
Jazz Pharmaceuticals
Rachel DEBS, MD
Centre de compétence Narcolepsies et Hypersomnies rares, CHU de Toulouse, Hôpital Pierre-Paul Riquet
James Maynard, MD
Community Research, Cincinnati, OH
Jan Ramaekers, PhD
Maastricht University
David Ward, MD
Aerial BioPharma, LLC